Study of stem cells in Waldenström macroglobulinemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at bone marrow stem cells in people with Waldenström macroglobulinemia (WM). It aims to understand how these cells work and may help improve future treatments for WM.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Waldenström macroglobulinemia (WM) using official criteria.
- You need to start treatment for WM within the next 3 months.
- You are willing to give your consent for the study.
- You are covered by a social security or health insurance plan.
- You do not have another type of blood cancer, like marginal zone lymphoma.
- Your WM has not changed into a different lymphoma (other than a specific type called diffuse large B-cell lymphoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a blood test called circulating tumor DNA, measured after 6 months of treatment, to see how well it predicts outcomes in people with Waldenström macroglobulinemia. It may help doctors better judge who is responding and who may need treatment adjustments earlier.
This study looks at “hyperviscosity,” meaning very thick blood, in people with Waldenström macroglobulinemia (WM). Your results may help doctors better understand who needs treatment and what tests should be used, even if thick blood is not found.
This study looks at medical records to understand what outcomes happen in people with Waldenström’s disease and how well certain factors predict those outcomes. It’s mainly about using past and planned follow-up data, which may help improve care for future patients.
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
This study is a registry that collects information about adults with certain IgM-related blood conditions. It may help doctors better understand these illnesses and improve future care.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.
Hear when a new Waldenström Macroglobuloinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.